Valion Bio, Inc.
- VBIO
- NASDAQ
- Biotechnology
- Acute Radiation Syndrome Treatment
- TLR5 Agonist (Entolimod)
$1.08
Today −7.69%Quote Oct 19, 2026, 02:02 PM UTC
−47.53%over the last month
Max drawdown −66.4%From 1-month high −66.4%3 months −87.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$24.0M
Quote Oct 19
Next earnings
Nov 13
Expected, not confirmed
Latest analyst target
—
Data unavailable
Floor
—
Data unavailable
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about VBIOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
52
Founded
2016